Diabetes drug may reduce heart attack risk in HIV patients

A diabetes drug may have benefits beyond lower blood sugar in patients with HIV. New research from the laboratory of Kevin E. Yarasheski, PhD, suggests the drug may prevent cardiovascular problems because it works to reduce inflammation that is linked to heart disease and stroke in these patients. The drug both improved metabolism and reduced inflammation in HIV-positive adults on antiretroviral therapy.
Vitamin D prevents diabetes and clogged arteries in mice

Vitamin D prevents diabetes and clogged arteries in mice

A deficiency of vitamin D has been linked to Type 2 diabetes and heart disease, two illnesses that commonly occur together and are the most common cause of illness and death in Western countries. Now, new research in mice led by the School of Medicine’s Carlos Bernal-Mizrachi suggests vitamin D plays a major role in preventing the inflammation that leads to Type 2 diabetes and atherosclerosis.

Study compares long-term effectiveness of diabetes drugs

Researchers at the School of Medicine are comparing the long-term benefits and risks of four widely used diabetes drugs given in combination with metformin, the most commonly prescribed medication for treating type 2 diabetes. The principal investigator at the St. Louis clinical site is Janet B. McGill, MD, who is pictured discussing options with study patient Michael Gingrich.

Cryer receives American Diabetes Association’s Renold Award

Philip E. Cryer, MD, will receive the American Diabetes Association’s Albert Renold Award at the organization’s 70th Scientific Sessions in Orlando, Fla. The Albert Renold Award is presented to an individual whose career is distinguished by outstanding achievements in the training of diabetes research scientists and the facilitation of diabetes research.